Skip to content Skip to left sidebar Skip to right sidebar Skip to footer


Development of recent HIV/AIDS screening technologies (transition from the manufacture of first generation tests to more effective third and fourth generation tests which take into account the genetic diversity of viral strains in Central Africa).

Expansion of the range of reagents usable in small health facilities with low technical capacity, such as public and private health centers.

Thanks to a technology transfer partnership with the French company for reagents and instruments (SFRI), specialized in human biology analyses, the IMPM has acquired a biotech unit for manufacturing biochemistry reagents and hematology systems adaptable to most machines available in national health facilities and the sub-region.